These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 32767050)
1. Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. Baumgartner JM; Riviere P; Lanman RB; Kelly KJ; Veerapong J; Lowy AM; Kurzrock R Ann Surg Oncol; 2020 Sep; 27(9):3259-3267. PubMed ID: 32767050 [TBL] [Abstract][Full Text] [Related]
2. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422 [TBL] [Abstract][Full Text] [Related]
3. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661 [TBL] [Abstract][Full Text] [Related]
4. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. Bansal VV; Belmont E; Godley F; Dhiman A; Witmer HD; Li S; Liao A; Eng OS; Turaga KK; Shergill A J Am Coll Surg; 2024 Jun; 238(6):1013-1020. PubMed ID: 38299640 [TBL] [Abstract][Full Text] [Related]
5. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585 [TBL] [Abstract][Full Text] [Related]
6. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer. Hassan F; Wang JH; O'Leary DP; Corrigan M; Redmond HP Surg Oncol; 2024 Jun; 54():102060. PubMed ID: 38603927 [TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma. Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901 [TBL] [Abstract][Full Text] [Related]
8. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868 [No Abstract] [Full Text] [Related]
9. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694 [TBL] [Abstract][Full Text] [Related]
10. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. Khakoo S; Carter PD; Brown G; Valeri N; Picchia S; Bali MA; Shaikh R; Jones T; Begum R; Rana I; Wotherspoon A; Terlizzo M; von Loga K; Kalaitzaki E; Saffery C; Watkins D; Tait D; Chau I; Starling N; Hubank M; Cunningham D Clin Cancer Res; 2020 Jan; 26(1):183-192. PubMed ID: 31852830 [TBL] [Abstract][Full Text] [Related]
11. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer. Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939 [TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634 [TBL] [Abstract][Full Text] [Related]
13. Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases. Baumgartner JM; Botta GP J Gastrointest Cancer; 2024 Mar; 55(1):41-46. PubMed ID: 37436640 [TBL] [Abstract][Full Text] [Related]
14. Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC). Chen K; Zhao H; Shi Y; Yang F; Wang LT; Kang G; Nie Y; Wang J Clin Cancer Res; 2019 Dec; 25(23):7058-7067. PubMed ID: 31439586 [TBL] [Abstract][Full Text] [Related]
15. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes. Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data. Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327 [TBL] [Abstract][Full Text] [Related]
17. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Newhook TE; Overman MJ; Chun YS; Dasari A; Tzeng CD; Cao HST; Raymond V; Parseghian C; Johnson B; Nishioka Y; Kawaguchi Y; Uppal A; Vreeland TJ; Jaimovich A; Arvide EM; Cristo JV; Wei SH; Raghav KP; Morris VK; Lee JE; Kopetz S; Vauthey JN Ann Surg; 2023 May; 277(5):813-820. PubMed ID: 35797554 [TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Pietrasz D; Wang-Renault S; Taieb J; Dahan L; Postel M; Durand-Labrunie J; Le Malicot K; Mulot C; Rinaldi Y; Phelip JM; Doat S; Blons H; de Reynies A; Bachet JB; Taly V; Laurent-Puig P Br J Cancer; 2022 Feb; 126(3):440-448. PubMed ID: 34811505 [TBL] [Abstract][Full Text] [Related]
20. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Ma F; Guan Y; Yi Z; Chang L; Li Q; Chen S; Zhu W; Guan X; Li C; Qian H; Xia X; Yang L; Zhang J; Husain H; Liao Z; Futreal A; Huang J; Yi X; Xu B Int J Cancer; 2020 Mar; 146(5):1359-1368. PubMed ID: 31241775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]